Abstract
Fifty years ago, the Eker rat was identified as the first animal model of hereditary renal adenoma and carcinoma [1], with histopathology resembling human renal carcinoma [2]. Ten years ago, a mutation in the TSC2 gene was identified in the Eker rat at Fox Chase Cancer Center by Yeung and Knudson [3], and in Tokyo by Kobayashi and Hino [4]. The literature contains dozens of reports of renal cell carcinoma (RCC) in tuberous sclerosis complex (TSC) patients, including tumors in children as young as five and one report in an infant. Despite these facts, the association between TSC and RCC is under-recognized, and sometimes completely omitted from discussions of inherited renal carcinoma. Here, we will review the clinical association of RCC in TSC, consider the factors that have led to its under-emphasis within the RCC field, address the cellular and biochemical mechanisms that may contribute to RCC in cells with TSC1 or TSC2 mutations, and finally discuss the ways in which the TSC signaling pathways may be linked to sporadic RCC in the general population.
Keywords: tuberous sclerosis complex, angiomyolipomas, renal cell carcinomas, polycystic kidney disease (pkd), birt-hogg-dube syndrome (bhd)
Current Molecular Medicine
Title: The Genetic Basis of Kidney Cancer: Why is Tuberous Sclerosis Complex Often Overlooked?
Volume: 4 Issue: 8
Author(s): Elizabeth Petri Henske
Affiliation:
Keywords: tuberous sclerosis complex, angiomyolipomas, renal cell carcinomas, polycystic kidney disease (pkd), birt-hogg-dube syndrome (bhd)
Abstract: Fifty years ago, the Eker rat was identified as the first animal model of hereditary renal adenoma and carcinoma [1], with histopathology resembling human renal carcinoma [2]. Ten years ago, a mutation in the TSC2 gene was identified in the Eker rat at Fox Chase Cancer Center by Yeung and Knudson [3], and in Tokyo by Kobayashi and Hino [4]. The literature contains dozens of reports of renal cell carcinoma (RCC) in tuberous sclerosis complex (TSC) patients, including tumors in children as young as five and one report in an infant. Despite these facts, the association between TSC and RCC is under-recognized, and sometimes completely omitted from discussions of inherited renal carcinoma. Here, we will review the clinical association of RCC in TSC, consider the factors that have led to its under-emphasis within the RCC field, address the cellular and biochemical mechanisms that may contribute to RCC in cells with TSC1 or TSC2 mutations, and finally discuss the ways in which the TSC signaling pathways may be linked to sporadic RCC in the general population.
Export Options
About this article
Cite this article as:
Henske Petri Elizabeth, The Genetic Basis of Kidney Cancer: Why is Tuberous Sclerosis Complex Often Overlooked?, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359610
DOI https://dx.doi.org/10.2174/1566524043359610 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Metabolic Imbalance of Homocysteine and Hydrogen Sulfide in Kidney Disease
Current Medicinal Chemistry Translational Multimodality Neuroimaging
Current Drug Targets Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development
Current Medicinal Chemistry Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine An Automated High-Throughput Sample Preparation Protocol for LC-MS/MS Analysis of Glycopeptides
Current Proteomics Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design